Linagliptin Metformin Duo Tablet 2.5/1000 mg
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jinyang Pharmaceutical Co., Ltd.
MFDS item code 202003651 · Approved 2020.05.19
This product's status changed to Expired on 2025.05.19. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of blood glucose control in adults with type 2 diabetes mellitus
This medication is used in conjunction with dietary and exercise therapy to help control blood sugar levels in adults with type 2 diabetes. It is particularly administered in cases where patients have not previously received diabetes medication or have difficulty controlling blood sugar with monotherapy. It can also be used when metformin monotherapy is not effective. This medication can be used as an alternative to combination therapy of linagliptin and metformin, and both medications can be administered together when control of blood sugar is insufficient despite combined treatment with metformin and sulfonylureas. When effects are insufficient even with combination therapy of insulin and metformin, this medication can be taken together with insulin. Finally, when blood sugar is not controlled with combination therapy of metformin and empagliflozin, it is used in conjunction with empagliflozin. This medication is useful for improving blood glucose control in conjunction with various treatment methods.
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose cannot be adequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients inadequately controlled with metformin monotherapy: The initial dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from concomitant linagliptin and metformin therapy: Patients switching from concomitant linagliptin and metformin therapy to this medicine should start at their existing doses of linagliptin and metformin. 4. Patients inadequately controlled with concomitant metformin and sulfonylurea therapy: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's existing metformin dose. When this medicine is coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with caution in the following patients). 5. Patients inadequately controlled with concomitant insulin and metformin therapy: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's existing metformin dose. When this medicine is coadministered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with caution in the following patients). No studies have been conducted to assess the safety and efficacy of switching patients from other oral antihyperglycemic agents to this medicine. Any change in type 2 diabetes treatment may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the initial dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 1. Do not administer to the following patients).
This medication may cause a serious side effect known as lactic acidosis, thus it should not be used in certain patients. For example, it should not be administered to patients who are allergic to the components of this medication, have type 1 diabetes, severe renal impairment, acute infections, liver dysfunction, acute alcohol intoxication, or are pregnant women. Due to the risk of hypoglycemia, caution is needed when combining this medication with medications that can induce hypoglycemia, such as sulfonylureas or insulin, and dosage adjustments may be required. Since this medication is excreted through the kidneys, regular monitoring of kidney function is necessary, and it is safer not to use this medication in patients with impaired kidney function. Patients with weak cardiac function should carefully monitor both cardiac and renal function while using this medication. The intake of the medication should be temporarily suspended before and after the administration of iodine contrast agents used in radiological examinations, and it should be resumed only after kidney function has stabilized. It is also safe to discontinue the intake of this medication for a certain period before and after surgery. Rare side effects such as acute pancreatitis or bullous pemphigoid may occur during the use of this medication; therefore, if abdominal pain or skin rashes develop, patients should immediately inform their doctor. Vitamin B12 levels may decrease, so it is advisable to regularly check vitamin B12 status during long-term use. It is recommended that pregnant or breastfeeding women do not use this medication, and if pregnancy is planned, consultation with a doctor is necessary. It is not recommended for children under 10 years of age or adolescents aged 10 to 17 years since safety and efficacy have not been established. Elderly patients may have decreased kidney function, so it is essential to start with the minimum dosage and monitor kidney function frequently. This medication may interact with other drugs; therefore, patients should inform their doctor or pharmacist of any medications they are currently taking. In case of overdose, lactic acidosis may occur, so immediate medical attention is required if symptoms appear. Store out of reach of children and keep away from moisture.
Lactic acidosis, pharyngitis, hypersensitivity, angioedema, urticaria, decreased and deficient vitamin B12, hypoglycemia, taste disorder, cough, decreased appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcer formation, abnormal liver function tests, hepatitis, pruritus, erythema, rash, vesiculobullous dermatitis, joint pain with severe and disability-associated, rhabdomyolysis, increased lipase, increased amylase, gastroenteritis, herpes zoster, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, constipation, upper abdominal pain, enterocolitis, intestinal obstruction, gastroenteritis, herpes zoster, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, speech disorder, Alzheimer's dementia, chest pain, fever, facial edema, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina pectoris, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, anxiety, mood disorders, insomnia, depression, contusion, bone contusion, concussion, bone fracture, hand fracture, laceration, palpitations, xerophthalmia, cataract, ocular discomfort, allergic conjunctivitis, polyuria, proteinuria, stress urinary incontinence, hematuria, hypotension, flushing, hepatic steatosis, cholelithiasis, hearing loss, erectile dysfunction, goiter, kidney transplant failure, anemia, dizziness, sensory loss, itching, hypertension, benign prostatic hyperplasia, confusional state, nocturia, dermatitis
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it should be stored in a tightly closed container. The storage temperature should be kept between 1 and 30 degrees Celsius at room temperature to maintain the medication's efficacy for an extended period.
Bright pink oval film-coated tablet
60 tablets/box[(10 tablets/PTPX6)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jinyang Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Anguk Pharm Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kukje Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.